ISCO (International Stem Cell) LT-Debt-to-Total-Asset: 0.00 (As of Mar. 2026)

What is International Stem Cell LT-Debt-to-Total-Asset?

International Stem Cell ISCO -5.88% 24 LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus rates ISCO with a GF Score™ of 24/100 and a GF Value™ of $0.13 (Modestly Overvalued). The stock has 6 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. International Stem Cell's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.00.

International Stem Cell's long-term debt to total assets ratio declined from Mar. 2025 (0.05) to Mar. 2026 (0.00). It may suggest that International Stem Cell is progressively becoming less dependent on debt to grow their business.

International Stem Cell (OTCPK:ISCO) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

International Stem Cell LT-Debt-to-Total-Asset Related Terms

International Stem Cell LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for International Stem Cell's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

International Stem Cell LT-Debt-to-Total-Asset Chart

International Stem Cell Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.19

0.14

0.08

0.02

0.00

International Stem Cell Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.05	0.04	0.02	0.00	0.00

24GF Score

International Stem Cell Corp ISCO

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

International Stem Cell LT-Debt-to-Total-Asset Calculation

International Stem Cell's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	0	/	4.819
	=	0.00

International Stem Cell's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	0	/	5.133
	=	0.00

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.00 mean?

International Stem Cell (ISCO) has a LT-Debt-to-Total-Asset of 0.00 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on International Stem Cell and its competitors.

Is International Stem Cell's LT-Debt-to-Total-Asset too high?

International Stem Cell's current LT-Debt-to-Total-Asset is 0.00. Overall, International Stem Cell has a GF Score™ of 24/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does International Stem Cell's LT-Debt-to-Total-Asset compare to ZVSA and AXIM?

International Stem Cell's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on International Stem Cell and its competitors. International Stem Cell's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is International Stem Cell stock overvalued right now?

Based on GuruFocus' analysis, International Stem Cell (ISCO) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.16 — trading 23.1% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. International Stem Cell's overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For International Stem Cell (ISCO), the current LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is International Stem Cell (ISCO) Overvalued in 2026?

Based on GuruFocus' analysis, International Stem Cell stock appears to be overvalued. The current stock price of $0.16 is trading 23.1% above its estimated GF Value™ of $0.13. GuruFocus considers International Stem Cell to be Modestly Overvalued.

Key valuation signals for ISCO:

LT-Debt-to-Total-Asset: 0.00
GF Value™: $0.13 vs. price of $0.16 (23.1% above fair value)
GF Score™: 24/100 with 6 warning signs

No single metric tells the full story. See the ISCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

International Stem Cell Business Description

Industry Healthcare Biotechnology

Comparable Companies ZVSA AXIM HEPA ABPO SCNI BPTH VBIO EVFM LYRA CLSDQ VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 9745 Businesspark Avenue, San Diego, CA, USA, 92131

Website https://www.internationalstemcell.com

International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. The company operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.

24GF Score

Get the complete analysis for ISCO

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.16

Price

$0.13

GF Value

View ISCO Analysis

See LT-Debt-to-Total-Asset data for all stocks →